再生元制药公司（Regeneron Pharmaceuticals，股票代码：REGN）今日盘中大涨5.05%，引发市场关注。尽管多家分析机构下调了该公司的目标股价，但依然保持了积极或中性的评级。
高盛维持对再生元制药的"买入"评级，尽管将目标价从917美元下调至804美元。富国银行保持"增持"评级，目标价从750美元调整至700美元。同时，Baird维持"中性"评级，将目标价从652美元下调至587美元。
分析人士认为，尽管目标价有所下调，但高盛维持"买入"评级并给出804美元的较高目标价，可能是推动再生元制药股价上涨的主要因素。这表明市场对该公司的长期发展前景仍然保持信心，即使在当前经济环境下，再生元制药的业务表现依然受到华尔街的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.